Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) Stock Has Average Price Target of $46.67

Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX – Get Free Report) has earned a consensus recommendation of “Moderate Buy” from the six ratings firms that are currently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and four have given a buy recommendation to the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $46.67.

A number of equities research analysts have weighed in on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Nanobiotix in a research report on Thursday, October 15th. Guggenheim started coverage on Nanobiotix in a research report on Tuesday, September 15th. They set a “buy” rating and a $64.00 price target on the stock.

Check Out Our Latest Stock Report on NBTX

Nanobiotix Stock Down 4.9%

NASDAQ:NBTX traded down $1.59 during midday trading on Tuesday, hitting $30.66. The stock had a trading volume of 93,105 shares, compared to its average volume of 151,759. Nanobiotix has a one year low of $19.14 and a one year high of $57.14. The stock has a 50-day moving average of $30.34 and a 200 day moving average of $34.20.

About Nanobiotix

(Get Free Report)

Nanobiotix is a French biotechnology company developing nanoparticle-based treatments for cancer. Founded in 2003, the company focuses on using nanomedicine to enhance the effects of established cancer therapies, particularly radiation therapy. Its lead product candidate, NBTXR3, is made from hafnium oxide nanoparticles and is designed to be injected directly into a tumor. When exposed to radiation, the particles are intended to increase damage to cancer cells while limiting the effect on surrounding healthy tissue.

See Also

Analyst Recommendations for Nanobiotix (NASDAQ:NBTX)

Receive News & Ratings for Nanobiotix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nanobiotix and related companies with MarketBeat.com's FREE daily email newsletter.